Double-digit growth in fee income cheered Singapore banks in Q4

Thanks to wealth management and capital market services.

Singapore banks were on a roll in Q4, as fee income grew 17%, 10%, and 23% YoY for OCBC, UOB, and DBS respectively.

For the full year, figures hit are 19%, 12%, and 12%, respectively.

Jefferies Singapore said the growth was driven by wealth management and capital market linked areas, like investment banking (IB) and fund management.

UOB also benefited from fees linked to credit cards. OCBC enjoyed strong growth in profits from life assurance, mainly in Q4 on the back of 23% growth in premiums and higher investment income from realized gains.

According to DBS' results, higher fee income was driven by wealth management fees from higher unit trust and other investment product sales.

Including trading income and gains from investment securities, overall non-interest income grew 23% and 8% for OCBC and UOB, respectively. DBS' non-interest income went up 1% for the whole year. 

Join Singapore Business Review community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Top News

DBS and OCBC expected to deliver steady Q1 net profits
Their net interest margins will ease as a result of their Hong Kong loans.
Singapore's maritime cluster navigates towards digital, green future
Adapting to emerging challenges, such as the adoption of alternative fuels, is deemed crucial for the country's maritime sector.
Shipping & Marine
SCG and A*STAR unveil joint labs for cellular immunotherapy enhancement
The partnership has a funding of nearly $30m supported under Singapore's Research, Innovation and Enterprise 2025 plan.
Healthcare